These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1888828)

  • 21. Colonic release of 5-amino salicylic acid from an oral preparation in active ulcerative colitis.
    Dew MJ; Ryder RE; Evans N; Evans BK; Rhodes J
    Br J Clin Pharmacol; 1983 Aug; 16(2):185-7. PubMed ID: 6615691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oroileal transit of slow release 5-aminosalicylic acid.
    Goebell H; Klotz U; Nehlsen B; Layer P
    Gut; 1993 May; 34(5):669-75. PubMed ID: 8504969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mesalazine release from coated tablets: effect of dietary fibre.
    Riley SA; Tavares IA; Bishai PM; Bennett A; Mani V
    Br J Clin Pharmacol; 1991 Aug; 32(2):248-50. PubMed ID: 1657094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Review article: new developments in the use of 5-aminosalicylic acid in patients with inflammatory bowel disease.
    Thomson AB
    Aliment Pharmacol Ther; 1991 Oct; 5(5):449-70. PubMed ID: 1793778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical pharmacokinetics of slow release mesalazine.
    De Vos M
    Clin Pharmacokinet; 2000 Aug; 39(2):85-97. PubMed ID: 10976656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.
    Brogden RN; Sorkin EM
    Drugs; 1989 Oct; 38(4):500-23. PubMed ID: 2684592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacology and pharmacokinetics of 5-aminosalicylic acid.
    Klotz U; Maier KE
    Dig Dis Sci; 1987 Dec; 32(12 Suppl):46S-50S. PubMed ID: 3319458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experience with Eudragit-S-coated mesalamine (Asacol) in inflammatory bowel disease. An open study.
    Faber SM; Korelitz BI
    J Clin Gastroenterol; 1993 Oct; 17(3):213-8. PubMed ID: 8228082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion.
    Staerk Laursen L; Stokholm M; Bukhave K; Rask-Madsen J; Lauritsen K
    Gut; 1990 Nov; 31(11):1271-6. PubMed ID: 2253912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New oral salicylates in the therapy of chronic idiopathic inflammatory bowel disease.
    Robinson MG
    Gastroenterol Clin North Am; 1989 Mar; 18(1):43-50. PubMed ID: 2646221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fecal radioiodide excretion following intravenous injection of 131-I-albumin and 125-I-immunoglobulin G in chronic inflammatory bowel disease. An aid to topographic diagnosis.
    Jarnum S; Jensen KB
    Gastroenterology; 1975 Jun; 68(6):1433-44. PubMed ID: 1132626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of Small Intestinal Transit Times in Ulcerative Colitis and Crohn's Disease Patients with Different Disease Activity Using Video Capsule Endoscopy.
    Fischer M; Siva S; Wo JM; Fadda HM
    AAPS PharmSciTech; 2017 Feb; 18(2):404-409. PubMed ID: 27032935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A pharmacokinetic study of sulphasalazine and two new formulations of mesalazine.
    Swift GL; Mills CM; Rhodes J; Evans BK; Bennett A; Tavares IA
    Aliment Pharmacol Ther; 1992 Apr; 6(2):259-66. PubMed ID: 1350926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased nitric oxide production and inducible nitric oxide synthase activity in colonic mucosa of patients with active ulcerative colitis and Crohn's disease.
    Kimura H; Miura S; Shigematsu T; Ohkubo N; Tsuzuki Y; Kurose I; Higuchi H; Akiba Y; Hokari R; Hirokawa M; Serizawa H; Ishii H
    Dig Dis Sci; 1997 May; 42(5):1047-54. PubMed ID: 9149061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of fecal granulocyte excretion in ulcerative colitis and Crohn's colitis.
    Saverymuttu SH; Hodgson HJ; Chadwick VS
    Dig Dis Sci; 1984 Nov; 29(11):1000-4. PubMed ID: 6489079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disposition of 5-aminosalicylic acid, the active metabolite of sulphasalazine, in man.
    Fischer C; Maier K; Stumpf E; von Gaisberg U; Klotz U
    Eur J Clin Pharmacol; 1983; 25(4):511-5. PubMed ID: 6140167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease.
    Daig R; Andus T; Aschenbrenner E; Falk W; Schölmerich J; Gross V
    Gut; 1996 Feb; 38(2):216-22. PubMed ID: 8801200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ColoPulse tablets perform comparably in healthy volunteers and Crohn's patients and show no influence of food and time of food intake on bioavailability.
    Maurer JM; Schellekens RC; van Rieke HM; Stellaard F; Wutzke KD; Buurman DJ; Dijkstra G; Woerdenbag HJ; Frijlink HW; Kosterink JG
    J Control Release; 2013 Dec; 172(3):618-24. PubMed ID: 24096020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral 5-aminosalicylic acid preparations in treatment of inflammatory bowel disease. An update.
    Martin F
    Dig Dis Sci; 1987 Dec; 32(12 Suppl):57S-63S. PubMed ID: 2891469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.